Your browser doesn't support javascript.
loading
ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.
Thunnissen, E; Lissenberg-Witte, B I; van den Heuvel, M M; Monkhorst, K; Skov, B G; Sørensen, J B; Mellemgaard, A; Dingemans, A M C; Speel, E J M; de Langen, A J; Hashemi, S M S; Bahce, I; van der Drift, M A; Looijen-Salamon, M G; Gosney, J; Postmus, P E; Samii, S M S; Duplaquet, F; Weynand, B; Durando, X; Penault-Llorca, F; Finn, S; Grady, A O; Oz, B; Akyurek, N; Buettner, R; Wolf, J; Bubendorf, L; Duin, S; Marondel, I; Heukamp, L C; Timens, W; Schuuring, E M D; Pauwels, P; Smit, E F.
Affiliation
  • Thunnissen E; Department of Pathology, Amsterdam UMC, Location VU University Medical Center, the Netherlands. Electronic address: e.thunnissen@amsterdamumc.nl.
  • Lissenberg-Witte BI; Epidemiology and Biostatistics, Amsterdam UMC, Location VU University Medical Center, the Netherlands.
  • van den Heuvel MM; Department of Thoracic Oncology Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
  • Monkhorst K; Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
  • Skov BG; Department of Pathology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Sørensen JB; Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Mellemgaard A; Department of Oncology, Herlev University Hospital, Copenhagen, Denmark.
  • Dingemans AMC; Department of Pulmonary Diseases, Maastricht University Medical Center, Maastricht, the Netherlands.
  • Speel EJM; Pathology, Maastricht University Medical Center, Maastricht, the Netherlands.
  • de Langen AJ; Department of Pulmonary Diseases, Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.
  • Hashemi SMS; Department of Pulmonary Diseases, Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.
  • Bahce I; Department of Pulmonary Diseases, Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.
  • van der Drift MA; Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Looijen-Salamon MG; Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Gosney J; Department of Pathology, Royal Liverpool University Hospital, Liverpool, United Kingdom.
  • Postmus PE; Department of medical oncology, Clatterbridge Cancer Centre, Bebington, Cheshire, United Kingdom.
  • Samii SMS; Department of Pulmonary Diseases, Deventer Hospital, Deventer, the Netherlands.
  • Duplaquet F; Department of Pneumology, CHU Mont-Godinne, Catholic University of Louvain (UCL), Yvoir, Belgium.
  • Weynand B; Pathology, CHU Mont-Godinne, Catholic University of Louvain (UCL), Yvoir, Belgium.
  • Durando X; Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.
  • Penault-Llorca F; Pathology, Centre Jean Perrin, Clermont-Ferrand, France.
  • Finn S; Department of Pathology, Trinity College Dublin, Dublin, Ireland.
  • Grady AO; Royal College of Surgeons in Ireland, Department of Pathology, Dublin, Ireland.
  • Oz B; Istanbul University Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, Turkey.
  • Akyurek N; Department of Pathology, Gazi University Medical Faculty, Ankara, Turkey.
  • Buettner R; Institute for Pathology, University Hospital Cologne, Köln, Germany.
  • Wolf J; Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Köln Bonn, Germany.
  • Bubendorf L; Institute of Pathology, University Hospital Basel, Basel, Switzerland.
  • Duin S; Department of Pathology, Amsterdam UMC, Location VU University Medical Center, the Netherlands.
  • Marondel I; Pfizer Innovative Health, Oncology - International Developed Markets, Berlin, Germany.
  • Heukamp LC; Institute of Haematopathology Hamburg, Hamburg, and Lung Cancer Network NOWEL.org, Oldenburg, Germany.
  • Timens W; Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Schuuring EMD; Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Pauwels P; Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
  • Smit EF; Department of Thoracic Oncology Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands; Department of Pulmonary Diseases, Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.
Lung Cancer ; 138: 13-18, 2019 12.
Article in En | MEDLINE | ID: mdl-31630043
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Crizotinib / Anaplastic Lymphoma Kinase / Lung Neoplasms Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Lung Cancer Journal subject: NEOPLASIAS Year: 2019 Document type: Article Country of publication: Ireland
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Crizotinib / Anaplastic Lymphoma Kinase / Lung Neoplasms Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Lung Cancer Journal subject: NEOPLASIAS Year: 2019 Document type: Article Country of publication: Ireland